Clinical trials: Gefitinib, completed
Brain and Central Nervous System Tumors
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
- Trial name
- NCT00016991
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.
- Trial name
- ICOGEN (NCT01040780)
- Testing
- Icotinib, Gefitinib
- Where
- 27 sites in China
- Volunteers
- 399 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Colorectal Cancer
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of ZD 1839 combined with irinotecan, leucovorin, and fluorouracil in treating patients who have locally advanced, locally recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00026364
- Testing
- fluorouracil, gefitinib, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
Stage IV Lung Cancer
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Lung Cancer is to become the first cause of death related to cancer in France as it's already the case in United States. At Present, Lung Cancer in women and in men is treated similarly.
- Trial name
- LADIE (NCT01556191)
- Testing
- Gefitinib, Fulvestrant, Erlotinib
- Where
- 61 sites in France
- Volunteers
- 379 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Hepatocellular Carcinoma, Molecular Targeted Therapy
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma.
- Trial name
- NCT04642547
- Testing
- Lenvatinib and Gefitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT00409006
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 7 sites in China, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Carcinoma (NSCLC)
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and effectiveness of Iressa when used with a short course of high dose radiation therapy in patients with lung cancer.
- Trial name
- NCT00328562
- Testing
- ZD1839 (Iressa), Thoracic Radiotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Unspecified Adult Solid Tumor, Protocol Specific
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00084786
- Testing
- docetaxel, gefitinib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a…
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02551718
- Testing
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Nasopharyngeal Carcinoma
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors.
- Trial name
- NCT00212108
- Testing
- celecoxib, gefitinib
- Where
- Singapore
- Volunteers
- 22 people
- Sponsor
- National University Hospital, Singapore
Lung Cancer
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00217698
- Testing
- cisplatin, gefitinib, gemcitabine hydrochloride
- Where
- 14 sites in Switzerland
- Volunteers
- 63 people
- Sponsor
- Swiss Cancer Institute
Esophageal Cancer
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with locally advanced…
- Trial name
- NCT00100945
- Testing
- gefitinib
- Where
- 119 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumor
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
This study is a single-arm,phase II study of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors. Gefitinib 250 mg will be administered orally daily.
- Trial name
- NCT02447419
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.
- Trial name
- NCT01000740
- Testing
- EGFR Mutation Test, Ki-67 protein expression
- Where
- 9 sites in China
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
The purpose of this study is to find out what effects (good and bad) ZD1839 has on one's squamous cell head and neck cancer. The research is being done because currently no effective treatment exists for metastatic (spread of…
- Trial name
- NCT01185158
- Testing
- ZD1839 (IRESSA)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer, Solid Tumors
A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR
The safety, tolerability and recommended phase 2 dose (RP2D) of the combination of gefitinib and BKM120 will be determined.
- Trial name
- BKM120 (NCT01570296)
- Testing
- Gefitinib and BKM120
- Where
- Singapore
- Volunteers
- 38 people
- Sponsor
- National Cancer Centre, Singapore
Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II trial to study the effectiveness of gefitinib in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00029003
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)